Tradjenta (Linagliptin)
Brand Names: Tradjenta
Methodology & AI Transparency ⓘ
Tradjenta (Linagliptin) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Tradjenta (Linagliptin) represents a prescription brand-name dipeptidyl peptidase 4 inhibitor entry registered by A-S Medication Solutions with package codes 50090-4383, 0597-0140.
- 2 Real-world patient consensus: Branded dipeptidyl peptidase 4 inhibitor presentation of Linagliptin (A-S Medication Solutions); generic reference: /meds/linagliptin.
- 3 Typical cash cost range: Public pharmacy ledger: $640.00 low cash benchmark vs. $1696.00 chain retail average ($16.7954/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Tradjenta (Linagliptin)): arthralgia (4.5%), nasopharyngitis (8.6%), nausea (8.3%).
Ask our AI Specialists anything about Tradjenta (Linagliptin)
Tradjenta (Linagliptin) Mechanism, CYP450 Pathways & DailyMed Monograph
Tradjenta (Linagliptin) represents a prescription brand-name dipeptidyl peptidase 4 inhibitor entry registered by A-S Medication Solutions with package codes 50090-4383, 0597-0140. Reviewed against 2024-01-22 FDA SPL standards (5 mg/1 Tablet, Film Coated; 5 mg), clinical deployment addresses 1 Indications and usage tradjenta: is indicated as an adjunct to diet and exercise to improve glycemic control in adults.
Tradjenta achieves therapeutic action via Linagliptin, engaging dipeptidyl peptidase 4 inhibitor physiological pathways involving CYP3A4/P-gp clearance pathways. Manufactured in 5 mg/1 Tablet, Film Coated; 5 mg (registered by A-S Medication Solutions, NDC 50090-4383, 0597-0140), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Tradjenta ($1696.00 retail) with generic Linagliptin ($640.00 low cash).
With Elimination kinetics span 5 to 13 hours per Tradjenta (Linagliptin) clinical pharmacology residence kinetics and Consistent 52%–64% gastrointestinal absorption profile for Tradjenta (Linagliptin) bioavailability, Tradjenta (Linagliptin) undergoes cytochrome cyp3a4, p-gp biotransformation with dual hepatorenal elimination and establishes therapeutic activity over cmax attained 2–5 hours post-administration of tradjenta (linagliptin).
Standard adult regimens span 5 mg/1 Tablet, Film Coated, 5 mg. Prescribers screen specifically against contraindicated in patients with prior serious allergic response to tradjenta (linagliptin) (ndc 50090-4383); severe baseline organ impairment where linagliptin accumulation exceeds safe therapeutic margins, while community micro-logs most frequently note nasopharyngitis (8.6% of reports), nausea (8.3% of reports), headache (7% of reports).
Rifampin or anticonvulsant inducers can diminish Tradjenta (Linagliptin) systemic exposure and clinical response.
Monitor serum digoxin concentrations when initiating or adjusting Tradjenta (Linagliptin) due to transporter overlap.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Tradjenta (Linagliptin) (NDC 50090-4383)
- Severe baseline organ impairment where Linagliptin accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (22 Reports)
Tradjenta (Linagliptin) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tradjenta (Linagliptin))
Human clinical trial evidence for Tradjenta (Linagliptin) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Tradjenta (Linagliptin) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $16.7954/unit (~$503.86/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Tradjenta (Linagliptin) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tradjenta (Linagliptin) RxNorm Concept ID | 1100702 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $16.7954 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 88.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tradjenta (Linagliptin) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Tradjenta (Linagliptin): FDA labeling (2024-01-22, NDC 50090-4383), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tradjenta (Linagliptin) community threads and patient logs by age, biological sex, dosage, and treatment duration.